ClinicalTrials.gg
CompletedNCT06383403ELSPIREUpdated Jul 9, 2026

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

A Phase 3 interventional study of Elafibranor and Placebo in Primary Biliary Cholangitis, sponsored by Ipsen. Completed at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Liver Cirrhosis, Biliary by Ipsen — 3 open to participants now, 6 under way, 3 of them phase 3. Liver Cirrhosis, Biliary · Ipsen.

Started
2024
with 1 other
Phase 3
4 of 10
1 open now
Registered
5th of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Ipsen, this one is one of 2 that started in 2024, is one of 4 in phase 3, and was the 5th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

3 of the 10 studies in Liver Cirrhosis, Biliary by Ipsen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Ipsen, or all of them as a file.
02

Study summary

The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.

Primary biliary cholangitis is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms.

Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment).

The main aim of this study is to determine if elafibranor is better than placebo in reducing ALP levels to a normal value. High ALP levels in the blood can indicate liver disease.

There will be three periods in this study: A screening period (up to 8 weeks) to assess whether the participant can take part; a treatment period (up to 52 weeks) where eligible participants will be grouped as per their blood ALP levels and randomly assigned to either receive elafibranor or placebo, and a follow-up period (4 weeks) where participants' health will be monitored.

Participants will be twice as likely to receive elafibranor than placebo (2:1 ratio).

Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a noninvasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (a noninvasive test that passes a probe on skin to measure stiffness of the liver).

They will also be asked to fill in questionnaires. Each participant will be in this study for up to 64 weeks (15 months).

03

Conditions studied

  • Primary Biliary Cholangitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants age ≥18 years of age.
  • Participants with a historical diagnosis of PBC as demonstrated by the presence of ≥2 of the following three historical diagnostic criteria:

    • i. History of elevated ALP levels for ≥6 months prior to the first screening visit (SV1).
    • ii. Positive Antimitochondrial antibody (AMA) titres (≥1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay) or positive PBC-specific antinuclear antibodies.
    • iii. Liver consistent with PBC.
  • ALP >1 × and \<1.67 × ULN.
  • Participants taking UDCA should have been on this medication for at least 6 months and at a stable dose for ≥3 months. Participants who are intolerant to UDCA should have taken the last dose of UDCA ≥3 months prior.
  • Participants taking medications for management of pruritus must be on a stable dose for ≥3 months.
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

    * (a) Male participants must agree that, if their partner is at risk of becoming pregnant, they will use an effective method of contraception. The participant must agree to use contraception during the whole period of the study and for 30 days after the last dose of study intervention.

  • Capable of giving signed

Exclusion criteria

Exclusion Criteria

  • History or presence of other concomitant liver diseases.
  • Participants with known cirrhosis who have a B or C score. Participants with cirrhosis with Child-Pugh A score are allowed.
  • History of liver transplantation.
  • History or presence of hepatic decompensation.
  • Known history of (HIV) infection.
  • Medical conditions that may cause non-hepatic increases in ALP (e.g. Paget's disease).
  • Evidence of any other unstable or untreated clinically significant conditions that are not well controlled.
  • Medical condition with a \<2 years.
  • Known or history of malignancy within the last 2 years, except for successfully treated localised basal cell carcinoma or squamous cell carcinoma of the skin; or in-situ carcinoma of the uterine cervix.
  • History of hepatocellular carcinoma.
  • Alpha-foetoprotein (AFP) >20 ng/mL with 4-phase liver computed tomography (CT) or magnetic resonance imaging (MRI) scans suggesting presence of liver cancer.
  • Administration of the following medications is prohibited during the study, and prior to the study as per the timelines specified below:

    * i. Systemic (oral or parenteral) use within 3 months prior to SV1 of: fibrates, seladelpar, glitazones, obeticholic acid, azathioprine, cyclosporine, methotrexate, mycophenolate, or long-term systemic (parenteral and oral chronic administration only); potentially hepatotoxic drugs (including α-methyl-dopa, valproic acid, isoniazid or nitrofurantoin)

  • Participants with previous exposure to elafibranor.
  • Participants who are currently participating in, plan to participate in, or have participated in an drug study or medical device study containing active substance within 30 days or 5 half-lives, whichever is longer.
  • Total (TB) >2 × . Participants with Gilbert's syndrome are eligible with a TB above 2 × ULN if direct bilirubin is \<30% of TB.
  • (ALT) and/or aspartate aminotransferase (AST) >5 × ULN.
  • Creatine phosphokinase (CPK) >2 × ULN.
  • count \<75,000/µL.
  • >1.3 in the absence of anticoagulant therapy.
  • Estimated (eGFR) \<45 mL/min/1.73m2.
  • Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as participants with evidence of significantly impaired kidney function or underlying kidney injury).

Other exclusions

  • For female participants: known pregnancy, or has a positive serum pregnancy test, or is breastfeeding.
  • Regular alcohol intake in excess of the recommended limit of 2 standard drinks per day for men or 1 standard drink per day for women.
  • History of alcohol abuse, or other substance abuse within 1 year prior.
  • Known to the investigational product or to any of the of elafibranor.
  • Mental instability or incompetence, such that the validity of or ability to be compliant with the study is uncertain.
  • Any other condition that, in the opinion of the investigator, would interfere with study participation or completion, or would put the participant at risk, including a potential participant assessed as being at high risk of noncompliance with the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Elafibranor 80 mg

    Participants will take 1 tablet of elafibranor 80 mg per day orally before breakfast with a glass of water at approximately the same time each morning.

    Drug: Elafibranor

  • Placebo comparator
    Placebo

    Participants will take 1 placebo tablet per day orally before breakfast with a glass of water at approximately the same time each morning.

    Other: Placebo

Interventions

  • Round and orange film coated tablet of 80 mg.

    Also known as: IPN60190

  • OtherPlacebo

    Round and orange film coated tablet of placebo

06

What researchers measure

Primary outcomes

  1. Percentage of participants with normalisation of Alkaline Phosphate (ALP) Levels

    Time frame: At Week 52

Secondary outcomes

  1. Percentage of participants with normalisation of ALP Levels

    Time frame: From baseline to Week 4, Week 12, Week 24 and Week 36

  2. Change from baseline in ALP levels

    Time frame: From baseline to Week 4, Week 12, Week 24, Week 36 and Week 52

  3. Percentage of participants with normalisation of ALP Levels and ≥15% decrease from Baseline

    Time frame: From baseline to Week 4, Week 12, Week 24, Week 36 and Week 52

  4. Percentage of participants with ≥40% decrease from Baseline in ALP Levels

    Time frame: From baseline to Week 4, Week 12, Week 24, Week 36 and Week 52

  5. Percentage of participants with ALP <0.5 × Upper Limit of Normal (ULN)

    Time frame: At Week 4, Week 12, Week 24, Week 36 and Week 52

  6. Changes from baseline in Total Bilirubin (TB) Levels

    Time frame: From baseline to Week 4, Week 12, Week 24, Week 36 and Week 52

  7. Percentage of participants with TB <0.7 × ULN

    Time frame: At Week 4, Week 12, Week 24, Week 36 and Week 52

  8. Percentage of participants with normalisation of ALP and TB <0.7 × ULN

    Time frame: At Week 4, Week 12, Week 24, Week 36 and Week 52

  9. Percentage of participants with normalisation of TB and ALP Levels

    Time frame: At Week 4, Week 12, Week 24, Week 36 and Week 52

  10. Percentage of participants with complete biochemical response

    Defined as normal levels of TB, ALP, aminotransferases, albumin, and International normalised ratio (INR)

    Time frame: At Week 4, Week 12, Week 24, Week 36 and Week 52

  11. Change from baseline in PBC Worst Itch Numeric Rating Scale (NRS) score

    PBC Worst Itch Numeric Rating Scale (NRS) is a self-administered patient-reported outcome questionnaire that measures itch intensity. It asks participants to rate the intensity of their Worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (Worst Itch imaginable): - once daily (24-hour recall period)

    Time frame: From baseline through Week 52

  12. Percentage of participants with moderate to severe pruritus at baseline (i.e. score ≥4) with a clinically meaningful response in PBC Worst Itch NRS

    Defined as ≥1.8-point reduction from baseline

    Time frame: From baseline through Week 52

  13. Change from baseline in 5-D itch score

    Change from baseline in symptoms in terms of 5 domains: degree, duration, direction, disability and distribution. Patients rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected.

    Time frame: From baseline to Week 4, Week 24, and Week 52

  14. Change from baseline in Patient Global Impression of Severity (PGI-S) scores

    Patient Global Impression of Severity (PGI-S) is a 1-item, 5-point scale designed to assess the participant's impression of itch severity over the past 7 days, at different time points during the study.

    Time frame: From baseline to Week 4, Week 24, and Week 52

  15. Patient Global Impression of Change (PGI-C) scores

    Patient Global Impression of Change (PGI-C) is a 1-item, 5-point scale designed to assess the participant's impression of change in itch severity since the baseline visit

    Time frame: At Week 4, Week 24, and Week 52

  16. Change from baseline in PBC-40 Quality of Life (QoL) scores

    PBC-40 Quality of Life (QoL) assesses symptoms across six domains: fatigue, emotional, social, cognitive function, general symptoms and itch. Patients respond on a verbal response scale, depending on the section options range from 'never' / 'not at all' / 'strongly disagree' to 'always' / 'very much'/ 'strongly agree'. Five items (3/3 in the itch domain and 2/10 in the social domain) also include a 'does not apply' option. A score for each domain is provided (but a total score is not calculated), with each verbal response scale correlating to a score of 1-5 per item (0-5 on items with a 'does not apply' option) with 5 being the most affected. The PBC-40 has a 4-week recall period.

    Time frame: From baseline to Week 4, Week 24, and Week 52

  17. Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a scores

    PROMIS Fatigue Short Form 7a scores consists of 7 items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Response options are on a 5-point Likert scale, ranging from 1 to 5. Scores can range from 7 to 35, with higher scores indicating greater fatigue.

    Time frame: From baseline to Week 4, Week 24, and Week 52

  18. Percentage of participants experiencing Treatment- Emergent Adverse Events (TEAEs), treatment- related TEAEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs).

    An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AESIs are AEs that may not be serious but are of special importance to a particular drug or class of drugs.

    Time frame: From baseline until 4 weeks after the end of treatment (maximum duration of 52 weeks)

  19. Percentage of participants developing clinically significant changes in physical examination

    The clinical significance will be graded by the investigator.

    Time frame: From baseline until 4 weeks after the end of treatment (maximum duration of 52 weeks)

  20. Percentage of participants developing clinically significant changes in vital signs

    The clinical significance will be graded by the investigator.

    Time frame: From baseline until 4 weeks after the end of treatment (maximum duration of 52 weeks)

  21. Percentage of participants developing clinically significant changes in Electrocardiogram (ECG) Readings

    The clinical significance will be graded by the investigator.

    Time frame: From baseline until 4 weeks after the end of treatment (maximum duration of 52 weeks)

  22. Percentage of participants developing clinically significant changes in laboratory parameters

    The following laboratory parameters will be reported: blood chemistry, hematology and coagulation, liver tests and renal tests (including urinalysis). The clinical significance will be graded by the investigator.

    Time frame: From baseline until 4 weeks after the end of treatment (maximum duration of 52 weeks)

07

Study locations

60 sites
  • Southern California Research Center
    Coronado, California 92118, United States
  • Topgraphy Health, Inc.
    Los Angeles, California 90005, United States
  • University of California, Davis
    Sacramento, California 95616, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80135, United States
  • Rocky Mountain Gastroenterology
    Littleton, Colorado 80120, United States
  • International Center for Research
    Tampa, Florida 33614, United States
  • Delta Research Partners, LLC
    West Monroe, Louisiana 71291, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Huron Gastroenterology Associates - Center for Digestive Care
    Ypsilanti, Michigan 48197, United States
  • South Denver Gastroenterology,P.C.
    Englewood, New Jersey 80113, United States
  • Southwest Gastroenterology Associates, PC (SWGA)
    Albuquerque, New Mexico 87109, United States
  • Northwell Health Center for Liver Disease and Transplantation
    Manhasset, New York 11030, United States
  • Charlotte Gastroenterology & Hepatology, PLLC
    Charlotte, North Carolina 28277, United States
  • Coastal Research Institute
    Fayetteville, North Carolina 28304, United States
  • Gastroenterology Center of the Midsouth
    Cordova, Tennessee 38018, United States
  • Methodist Transplant Physicians
    Dallas, Texas 75203, United States
  • American Research Corporation at The Texas Liver Institute
    San Antonio, Texas 78215, United States
  • American Research Corporation
    San Antonio, Texas 78215, United States
  • Velocity Liver Institute NW
    Seattle, Washington 98105, United States
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Králové, Czechia
  • Artroscan
    Ostrava, Czechia
  • Research Site s.r.o.
    Pilsen, Czechia
  • Institute for Clinical and Experimental Medicine - IKEM
    Prague, Czechia
  • Clinique Pasteur
    Toulouse, France
  • Universitatsklinikum Heidelberg
    Heidelberg, Germany
  • Gastroenterologsiche Studiengesellschaft Herne
    Hemer, Germany
  • EUGASTRO GmbH
    Leipzig, Germany
  • Universitaetsklinikum Muenster
    Münster, Germany
  • Ospedale Policlinico San Martino - IRCCS
    Genova, Italy
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
    Palermo, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Italy
  • IRCCS Istituto clinico humanitas - Humanitas Mirasole spa
    Rozzano, Italy
  • Krakowskie Centrum Medyczne Sp.z.o.o - FutureMeds
    Krakow, Poland
  • FutureMeds Warszawa Centrum
    Warsaw, Poland
  • Cluj County Clinical Emergency Hospital
    Cluj-Napoca, Romania
  • Gastromedica Srl
    Iași, Romania
  • Korea University Ansan Hospital
    Ansan-si, South Korea
  • Keimyung University Dongsan Hospital
    Daegu, South Korea
  • Kyungpook National University Hospital (KNUH)
    Daegu, South Korea
  • Pusan National University Hospital (PNUH)
    Pusan, South Korea
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, South Korea
  • Seoul National University Bundang Hospital (SNUBH)
    Seongnam-si, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, South Korea
  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital
    Seoul, South Korea
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Hospital Universitario Puerta de Hierro de Majadahonda
    Majadahonda, Spain
  • Institut d Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Tauli
    Sabadell, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, Spain
  • Aberdeen Royal Infirmary NHS Grampian Grampian Health Board
    Aberdeen, United Kingdom
  • Bradford Royal Infirmary - Bradford Teaching Hospitals NHS Foundation
    Bradford, United Kingdom
  • Frimley Park Hospital - Frimley Health NHS Foundation Trust
    Frimley, United Kingdom
  • Queen Elizabeth University Hospital - Greater Glasgow Health Board
    Glasgow, United Kingdom
  • Hull Royal Infirmary - Hull University Teaching Hospitals NHS Trust
    Hull, United Kingdom
  • Ambrose King Centre-Royal London Hospital-Barts Health NHS Trust
    London, United Kingdom
  • King's College Hospital
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jun 2026, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Jul 9, 2024
Primary completionActual
Jun 16, 2026
CompletionActual
Jun 16, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06383403
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Jul 9, 2024
Primary completion
Jun 16, 2026
Completion
Jun 16, 2026
Last update
Jul 9, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion